Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.7824 |
Intermediate Similarity |
NPD6851 |
Approved |
0.7824 |
Intermediate Similarity |
NPD6853 |
Approved |
0.7812 |
Intermediate Similarity |
NPD7132 |
Clinical (unspecified phase) |
0.7801 |
Intermediate Similarity |
NPD6297 |
Approved |
0.7755 |
Intermediate Similarity |
NPD2843 |
Phase 2 |
0.7755 |
Intermediate Similarity |
NPD2845 |
Phase 2 |
0.7751 |
Intermediate Similarity |
NPD8149 |
Discontinued |
0.7667 |
Intermediate Similarity |
NPD5561 |
Approved |
0.7667 |
Intermediate Similarity |
NPD5562 |
Approved |
0.7619 |
Intermediate Similarity |
NPD7559 |
Phase 2 |
0.7586 |
Intermediate Similarity |
NPD7255 |
Clinical (unspecified phase) |
0.755 |
Intermediate Similarity |
NPD3631 |
Phase 3 |
0.7548 |
Intermediate Similarity |
NPD3591 |
Approved |
0.7548 |
Intermediate Similarity |
NPD3592 |
Approved |
0.7512 |
Intermediate Similarity |
NPD3106 |
Clinical (unspecified phase) |
0.7487 |
Intermediate Similarity |
NPD4083 |
Discontinued |
0.7455 |
Intermediate Similarity |
NPD3442 |
Approved |
0.7455 |
Intermediate Similarity |
NPD3441 |
Approved |
0.7454 |
Intermediate Similarity |
NPD6824 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD5525 |
Clinical (unspecified phase) |
0.7402 |
Intermediate Similarity |
NPD6877 |
Discontinued |
0.7376 |
Intermediate Similarity |
NPD6046 |
Clinical (unspecified phase) |
0.7359 |
Intermediate Similarity |
NPD7859 |
Phase 2 |
0.7356 |
Intermediate Similarity |
NPD5102 |
Clinical (unspecified phase) |
0.7344 |
Intermediate Similarity |
NPD7608 |
Discontinued |
0.7323 |
Intermediate Similarity |
NPD7281 |
Phase 3 |
0.7323 |
Intermediate Similarity |
NPD7280 |
Phase 3 |
0.7317 |
Intermediate Similarity |
NPD5071 |
Phase 2 |
0.7316 |
Intermediate Similarity |
NPD6533 |
Clinical (unspecified phase) |
0.7304 |
Intermediate Similarity |
NPD7667 |
Clinical (unspecified phase) |
0.7302 |
Intermediate Similarity |
NPD6063 |
Approved |
0.7297 |
Intermediate Similarity |
NPD7131 |
Phase 3 |
0.7277 |
Intermediate Similarity |
NPD7225 |
Discontinued |
0.7264 |
Intermediate Similarity |
NPD6608 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD5025 |
Approved |
0.7238 |
Intermediate Similarity |
NPD7174 |
Clinical (unspecified phase) |
0.7216 |
Intermediate Similarity |
NPD2215 |
Approved |
0.7216 |
Intermediate Similarity |
NPD2216 |
Approved |
0.7214 |
Intermediate Similarity |
NPD8103 |
Clinical (unspecified phase) |
0.7202 |
Intermediate Similarity |
NPD7485 |
Phase 3 |
0.7202 |
Intermediate Similarity |
NPD7484 |
Phase 3 |
0.7192 |
Intermediate Similarity |
NPD5641 |
Discontinued |
0.719 |
Intermediate Similarity |
NPD6644 |
Discontinued |
0.7188 |
Intermediate Similarity |
NPD4885 |
Approved |
0.7184 |
Intermediate Similarity |
NPD4604 |
Approved |
0.7184 |
Intermediate Similarity |
NPD4605 |
Approved |
0.7181 |
Intermediate Similarity |
NPD7729 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD3296 |
Phase 1 |
0.717 |
Intermediate Similarity |
NPD5658 |
Approved |
0.7164 |
Intermediate Similarity |
NPD3154 |
Approved |
0.7164 |
Intermediate Similarity |
NPD3153 |
Approved |
0.7163 |
Intermediate Similarity |
NPD6612 |
Phase 2 |
0.7157 |
Intermediate Similarity |
NPD3633 |
Approved |
0.7157 |
Intermediate Similarity |
NPD3634 |
Approved |
0.7156 |
Intermediate Similarity |
NPD8318 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD6377 |
Clinical (unspecified phase) |
0.7143 |
Intermediate Similarity |
NPD5602 |
Clinical (unspecified phase) |
0.7129 |
Intermediate Similarity |
NPD4084 |
Clinical (unspecified phase) |
0.7124 |
Intermediate Similarity |
NPD6963 |
Approved |
0.7124 |
Intermediate Similarity |
NPD6964 |
Approved |
0.7123 |
Intermediate Similarity |
NPD7263 |
Phase 2 |
0.7121 |
Intermediate Similarity |
NPD7479 |
Phase 2 |
0.7113 |
Intermediate Similarity |
NPD2821 |
Approved |
0.7101 |
Intermediate Similarity |
NPD4979 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD6795 |
Clinical (unspecified phase) |
0.7089 |
Intermediate Similarity |
NPD8091 |
Phase 3 |
0.7081 |
Intermediate Similarity |
NPD6519 |
Phase 2 |
0.7062 |
Intermediate Similarity |
NPD7201 |
Clinical (unspecified phase) |
0.7059 |
Intermediate Similarity |
NPD5896 |
Clinical (unspecified phase) |
0.7056 |
Intermediate Similarity |
NPD5966 |
Clinical (unspecified phase) |
0.7049 |
Intermediate Similarity |
NPD7153 |
Discontinued |
0.7039 |
Intermediate Similarity |
NPD4539 |
Phase 1 |
0.7033 |
Intermediate Similarity |
NPD5547 |
Clinical (unspecified phase) |
0.7028 |
Intermediate Similarity |
NPD7891 |
Discontinued |
0.7023 |
Intermediate Similarity |
NPD4997 |
Clinical (unspecified phase) |
0.7023 |
Intermediate Similarity |
NPD5645 |
Phase 3 |
0.701 |
Intermediate Similarity |
NPD3349 |
Phase 2 |
0.701 |
Intermediate Similarity |
NPD4157 |
Discontinued |
0.701 |
Intermediate Similarity |
NPD7291 |
Discontinued |
0.7005 |
Intermediate Similarity |
NPD4413 |
Clinical (unspecified phase) |
0.7005 |
Intermediate Similarity |
NPD6365 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD7025 |
Clinical (unspecified phase) |
0.6996 |
Remote Similarity |
NPD7821 |
Clinical (unspecified phase) |
0.6995 |
Remote Similarity |
NPD7607 |
Clinical (unspecified phase) |
0.699 |
Remote Similarity |
NPD5186 |
Approved |
0.699 |
Remote Similarity |
NPD5183 |
Approved |
0.6982 |
Remote Similarity |
NPD8311 |
Discontinued |
0.6979 |
Remote Similarity |
NPD5773 |
Approved |
0.6979 |
Remote Similarity |
NPD5772 |
Approved |
0.6976 |
Remote Similarity |
NPD7617 |
Discontinued |
0.6971 |
Remote Similarity |
NPD8249 |
Clinical (unspecified phase) |
0.6968 |
Remote Similarity |
NPD7858 |
Clinical (unspecified phase) |
0.6952 |
Remote Similarity |
NPD7811 |
Phase 3 |
0.6952 |
Remote Similarity |
NPD7810 |
Phase 3 |
0.6942 |
Remote Similarity |
NPD6656 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD3511 |
Discontinued |
0.6931 |
Remote Similarity |
NPD6031 |
Approved |
0.6931 |
Remote Similarity |
NPD6030 |
Approved |
0.693 |
Remote Similarity |
NPD6494 |
Phase 2 |
0.693 |
Remote Similarity |
NPD4154 |
Approved |
0.693 |
Remote Similarity |
NPD8027 |
Approved |
0.6915 |
Remote Similarity |
NPD6211 |
Clinical (unspecified phase) |
0.6913 |
Remote Similarity |
NPD6982 |
Phase 2 |
0.6912 |
Remote Similarity |
NPD4206 |
Approved |
0.6912 |
Remote Similarity |
NPD6339 |
Approved |
0.6912 |
Remote Similarity |
NPD6340 |
Approved |
0.6904 |
Remote Similarity |
NPD4606 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD5917 |
Clinical (unspecified phase) |
0.6895 |
Remote Similarity |
NPD5903 |
Approved |
0.6895 |
Remote Similarity |
NPD5902 |
Approved |
0.6892 |
Remote Similarity |
NPD5930 |
Phase 3 |
0.6891 |
Remote Similarity |
NPD6818 |
Clinical (unspecified phase) |
0.6889 |
Remote Similarity |
NPD7426 |
Phase 1 |
0.6887 |
Remote Similarity |
NPD6238 |
Discontinued |
0.6881 |
Remote Similarity |
NPD7827 |
Phase 1 |
0.6881 |
Remote Similarity |
NPD7178 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD7820 |
Phase 3 |
0.6875 |
Remote Similarity |
NPD7262 |
Phase 1 |
0.6875 |
Remote Similarity |
NPD3912 |
Discontinued |
0.6875 |
Remote Similarity |
NPD7125 |
Discontinued |
0.6872 |
Remote Similarity |
NPD7589 |
Clinical (unspecified phase) |
0.6863 |
Remote Similarity |
NPD6618 |
Phase 2 |
0.6859 |
Remote Similarity |
NPD5811 |
Approved |
0.6856 |
Remote Similarity |
NPD5967 |
Approved |
0.6853 |
Remote Similarity |
NPD6107 |
Approved |
0.685 |
Remote Similarity |
NPD4498 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD6662 |
Clinical (unspecified phase) |
0.6838 |
Remote Similarity |
NPD7620 |
Phase 2 |
0.6832 |
Remote Similarity |
NPD5445 |
Approved |
0.6828 |
Remote Similarity |
NPD4162 |
Approved |
0.6825 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6822 |
Remote Similarity |
NPD3802 |
Phase 3 |
0.682 |
Remote Similarity |
NPD8463 |
Approved |
0.6818 |
Remote Similarity |
NPD4166 |
Phase 2 |
0.6818 |
Remote Similarity |
NPD5847 |
Phase 1 |
0.6816 |
Remote Similarity |
NPD5313 |
Approved |
0.6816 |
Remote Similarity |
NPD3965 |
Phase 1 |
0.6816 |
Remote Similarity |
NPD5312 |
Approved |
0.6816 |
Remote Similarity |
NPD3437 |
Discontinued |
0.6816 |
Remote Similarity |
NPD5334 |
Clinical (unspecified phase) |
0.6814 |
Remote Similarity |
NPD7546 |
Discontinued |
0.6814 |
Remote Similarity |
NPD7877 |
Suspended |
0.6812 |
Remote Similarity |
NPD4258 |
Approved |
0.6812 |
Remote Similarity |
NPD4259 |
Approved |
0.681 |
Remote Similarity |
NPD5582 |
Discontinued |
0.6808 |
Remote Similarity |
NPD3416 |
Discontinued |
0.6806 |
Remote Similarity |
NPD7453 |
Approved |
0.6806 |
Remote Similarity |
NPD6296 |
Discontinued |
0.6806 |
Remote Similarity |
NPD7452 |
Approved |
0.6806 |
Remote Similarity |
NPD7222 |
Phase 2 |
0.6804 |
Remote Similarity |
NPD6060 |
Clinical (unspecified phase) |
0.6798 |
Remote Similarity |
NPD7038 |
Approved |
0.6798 |
Remote Similarity |
NPD5192 |
Clinical (unspecified phase) |
0.6798 |
Remote Similarity |
NPD7039 |
Approved |
0.6792 |
Remote Similarity |
NPD6874 |
Approved |
0.6789 |
Remote Similarity |
NPD7527 |
Clinical (unspecified phase) |
0.6789 |
Remote Similarity |
NPD7526 |
Approved |
0.6789 |
Remote Similarity |
NPD52 |
Approved |
0.6788 |
Remote Similarity |
NPD7109 |
Clinical (unspecified phase) |
0.6788 |
Remote Similarity |
NPD7110 |
Phase 1 |
0.6788 |
Remote Similarity |
NPD7118 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD6560 |
Approved |
0.6786 |
Remote Similarity |
NPD7805 |
Phase 3 |
0.6786 |
Remote Similarity |
NPD8031 |
Discontinued |
0.6783 |
Remote Similarity |
NPD6625 |
Approved |
0.6777 |
Remote Similarity |
NPD7955 |
Approved |
0.6777 |
Remote Similarity |
NPD7956 |
Approved |
0.6777 |
Remote Similarity |
NPD7034 |
Discontinued |
0.6774 |
Remote Similarity |
NPD7596 |
Clinical (unspecified phase) |
0.6768 |
Remote Similarity |
NPD6457 |
Approved |
0.6763 |
Remote Similarity |
NPD5620 |
Clinical (unspecified phase) |
0.6763 |
Remote Similarity |
NPD8255 |
Phase 2 |
0.6763 |
Remote Similarity |
NPD5188 |
Clinical (unspecified phase) |
0.6753 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.675 |
Remote Similarity |
NPD4926 |
Clinical (unspecified phase) |
0.6746 |
Remote Similarity |
NPD4740 |
Approved |
0.6746 |
Remote Similarity |
NPD5587 |
Approved |
0.6744 |
Remote Similarity |
NPD7597 |
Clinical (unspecified phase) |
0.6738 |
Remote Similarity |
NPD2458 |
Approved |
0.6738 |
Remote Similarity |
NPD2460 |
Phase 3 |
0.6738 |
Remote Similarity |
NPD2459 |
Approved |
0.6733 |
Remote Similarity |
NPD3793 |
Phase 3 |
0.6731 |
Remote Similarity |
NPD3408 |
Clinical (unspecified phase) |
0.6726 |
Remote Similarity |
NPD8405 |
Clinical (unspecified phase) |
0.6726 |
Remote Similarity |
NPD7278 |
Phase 2 |
0.6726 |
Remote Similarity |
NPD7279 |
Phase 2 |
0.6723 |
Remote Similarity |
NPD6517 |
Phase 3 |
0.6716 |
Remote Similarity |
NPD6720 |
Clinical (unspecified phase) |
0.6716 |
Remote Similarity |
NPD5938 |
Phase 3 |
0.6714 |
Remote Similarity |
NPD5150 |
Phase 2 |
0.6712 |
Remote Similarity |
NPD6744 |
Clinical (unspecified phase) |
0.6709 |
Remote Similarity |
NPD8016 |
Phase 3 |
0.6709 |
Remote Similarity |
NPD8017 |
Clinical (unspecified phase) |
0.67 |
Remote Similarity |
NPD5680 |
Clinical (unspecified phase) |
0.67 |
Remote Similarity |
NPD5137 |
Approved |
0.6699 |
Remote Similarity |
NPD6045 |
Phase 3 |
0.6699 |
Remote Similarity |
NPD6021 |
Clinical (unspecified phase) |
0.6698 |
Remote Similarity |
NPD7316 |
Discontinued |
0.6698 |
Remote Similarity |
NPD956 |
Clinical (unspecified phase) |
0.6698
|
Remote Similarity |
NPD6621 |
Clinical (unspecified phase) |